An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
Conditions
Acute Myeloid Leukemia (AML)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
AKH - Medizinische Universität Wien, Vienna, Austria
Klinikum Wels-Grieskirchen GmbH, Wels, Austria
Institut Paoli Calmettes, Marseille, Bouches-du-Rhône, France
CHU CAEN - Hôpital de la Côte de Nacre, Caen, Calvados, France
CHU de Toulouse pt, Toulouse, Haute Garonne, France
CHU Rennes - Hopital Pontchaillou, Rennes, Ille Et Vilaine, France
CHU Angers - Hôpital Hôtel Dieu, Angers, Liore, France
IRCCS Istituto Scientifico Romagnolo Per Lo Studio Dei Tumori "Dino Amadori" - IRST, Meldola, Forli-Cesena, Italy
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili), Brescia, Italy
IRCCS Ospedale Policlinico San Martino, Genova, Italy
Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia, Perugia, Italy
Meander Medisch Centrum, Amersfoort, Netherlands
Amsterdam UMC, Amsterdam, Netherlands
Rijnstate, Arnhem, Netherlands
Universitair Medisch Centrum Groningen, Groningen, Netherlands